CollPlant Biotechnologies Ltd. has entered into definitive agreements for the private placement to issuance of 989,301 Ordinary Shares at the price of $3.74 for the gross proceeds of $3,699,985.74 and ...

The Parisian biotech company specializing in inflammatory diseases is recovering ground mid-morning, following several weeks ...

The Paris-based biotech company specializing in nanomedicine for oncology extends its downward slide at midday, in an SBF 120 ...

Susan Bobulsky is identified as an officer of Adaptive Biotechnologies Corporation. Shares proposed for sale: 6,444 common ...

Adaptive Biotechnologies Corp’s stock reached a 52-week high, hitting $30.10, marking a significant milestone for the company ...

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune s ...

Learn more about whether Adaptive Biotechnologies Corporation or Fortrea Holdings Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Fintel reports that on 29 September 2026, Goldman Sachs initiated coverage of Adaptive Biotechnologies (MUN:1HM) with a Buy recommendation. Adaptive Biotechnologies Corporation, based in the United ...

The 5,000m² facility, located at Michelin’s Innovation Park – Cataroux, has begun welcoming its first advanced fermentation ...

The average one-year price target for Adaptive Biotechnologies (NASDAQGS:ADPT) (MUN:1HM) has been revised to $28.05 / share. This is an increase of 11.11% from the prior estimate of $25.24 dated ...

Guggenheimanalyst Subbu Nambi maintains $Adaptive Biotechnologies(ADPT.US)$ with a buy rating, and adjusts the target price ...

Adaptive Biotechnologies Corporation (ADPT) is down 3.5% today. Here is some analysis on what might have caused this price movement. Analysis: The catalyst is not fully clear, but the move appears ...